Zevra Therapeutics (ZVRA) Capital Expenditures (2014 - 2026)

Zevra Therapeutics (ZVRA) has 12 years of Capital Expenditures data on file, last reported at $35000.0 in Q1 2026.

• Quarterly Capital Expenditures fell 64.65% year-over-year to $35000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $771000.0 (up 678.79% YoY) and the FY2025 annual result came in at $835000.0, changed N/A from the prior year.
• Capital Expenditures climbed to $35000.0 in Q1 2026, from -$31000.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $10.5 million in Q2 2022 to a low of -$10.5 million in Q1 2022.
• A 4-year average of $60000.0 and a median of $35000.0 in 2026 frame the typical range for Capital Expenditures.
• The widest YoY moves for Capital Expenditures: up 58327.78% in 2022, down 262250.0% in 2022.
• Tracing ZVRA's Capital Expenditures over 4 years: stood at -$445000.0 in 2022, then jumped by 116.18% to $72000.0 in 2023, then tumbled by 143.06% to -$31000.0 in 2025, then jumped by 212.9% to $35000.0 in 2026.
• The last three Capital Expenditures figures came in at $35000.0 (Q1 2026), -$31000.0 (Q4 2025), and $554000.0 (Q3 2025), per Business Quant data.